Towards Healthcare
Multiple Myeloma CAR-T Market Trends 2025 Forecast Strong CAGR

Multiple Myeloma CAR-T Market 2025 Outlook Strengthened by AstraZeneca and Moffitt Cancer Center Strategic Partnership

The market is growing due to the strong clinical success of BCMS-targeted therapies and rising cases of relapsed or refractory patients. Improved regulatory support and expanded treatment access are further accelerating market adoption. 

Content

  • Insight Code: 5812
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

Global multiple myeloma CAR-T market set for major growth by 2034, fueled by innovation and increased funding.

North America is currently leading the healthcare cybersecurity market due to its advanced healthcare infrastructure, early adoption of cutting-edge therapies, and presence of major CAR T developers.

The multiple myeloma CAR-T market includes eight segments by component, by targeted antigen, by product type, by line of therapy, by distribution channel, by technology/Vector type, by manufacturing type, by end-user, and by region.

Some key players include Pfizer Inc., Gilead Sciences (Kite Pharma), Autolus Therapeutics, Poseida Therapeutics, and Bluebird Bio. 

Key trends include the growth due to the strong clinical success of BCMS-targeted therapies and rising cases of relapsed or refractory patients.

As of now, Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) are approved by regulatory authorities like the FDA for treating multiple myeloma.

CAR-T therapies have shown high response rates in clinical trials, especially in patients who have failed multiple prior treatments. However, long-term remission is still under study.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.
Any Questions